Table 2.
Variables related to seroresponse
| Reference | SOT recipients | Transplant type (n) | Seroresponse after first vaccination, % | Seroresponse after second vaccination, % | BNT162b2 vaccinated, n | BNT162b2 seroconverted, n | mRNA-1273 vaccinated, n | mRNA-1273 seroconverted, n | Immunological assay | Cutoff seronversion | Median time between second vaccination and measuring the antibody response |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Boyarsky et al. [15] | 658a | Kidney (322) Liver (129) Heart (97) Lung (71) Pancreas (5) Multiorgan (26) Missing data (8) |
15 | 54 | 342 | 167 | 307 | 183 | Roche Elecsys (anti-RBD total Ab) OR Euroimmun (anti-S1 IgG) | ≥0.8 U/mL (Roche Elecsys) ≥1:1 AUs (Euroimmun) |
29 days |
| Dębska-Ślizień et al. [16] | 142 | Kidney (142) | NA | 51 | 105 | 50 | 37 | 23 | DiaSorin (anti-trimeric S-protein test) | ≥12 AU/mL | 14–21 days |
| Hallett et al. [17] | 237 | Heart (134) | 14 | 48 | 70 | 42 | 64 | 41 | Roche Elecsys (anti-RBD total Ab) OR Euroimmun (anti-S1 IgG) | ≥0.8 U/mL (Roche Elecsys) ≥1:1 AUs (Euroimmun) |
29 days |
| Lung (103) | 9 | 27 | 56 | 19 | 47 | 18 | |||||
| Narasimhan et al. [18] | 73 | Lung (73) | NA | 25 | 48 | 9 | 25 | 9 | Abbott Alinity i (anti-RBD IgG) | ≥50 AU/mL | 17.5 days (BNT162b) 19 days (mRNA-1273) |
| Strauss et al. [19] | 161 | Liver (161) | 34 | 81 | 85 | 62 | 76 | 68 | Roche Elecsys (anti-RBD total Ab) or Euroimmun (anti-S1 IgG) | ≥0.8 U/mL (Roche Elecsys) ≥1:1 AUs (Euroimmun) |
30 days |
| Stumpf et al. [20] | 368a | Kidney (368) | 8 | 42 | 99 | 26 | 234 | 114 | Euroimmun (anti-S1 IgG or anti-S1 IgA) | A positive serologic response was defined as de novo antibody development (seroconversion) | 4–5 weeks |
| Wijtvliet et al. [21] | 133 | Kidney (133) | 14 | 62 | 91 | 51 | 42 | 32 | Luminex (anti-RBD IgG) | Signal:noise ratio > 1 | 28 days |
| Yi et al. [14] | 105 | Kidney (105) | NA | 36 | 60 | 20 | 45 | 18 | Ortho Clinical Diagnostics anti-SARS-CoV-2 Spike Ig assay | Antibody response was defined as the presence of either anti-SARS-CoV-2 IgG or total antibody or anti-SARS-CoV-2 Spike total Ig ≥ 1:50 | 91 days |
Ab, antibodies; AU, arbitrary units; Ig, immunoglobulin; S-protein, spike protein.
aVaccine-specific seroconversion rate not available from all included patients.